| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/04/2003 | US20030166670 Admininstering opioids to treat and ameliorate the symptoms of a neurologic or neurogenic syndrome, e.g., lingual, pharyngeal, laryngeal, esophageal, urinary bladder sphincter, lumbar-sacral spine, pelvis-limb paresis or paralysis |
| 09/04/2003 | US20030166668 Substituted heteroarylalkanoic acids |
| 09/04/2003 | US20030166667 Potent ameliorating effect on dementia among the known BZ omega 3 receptor agonists and on learning and/or memory impairments induced by hypofunction of glutamatergic system or cholinergic system; Alzheimer's; cognition activators |
| 09/04/2003 | US20030166666 Diimino-piperazine derivatives for use as modulators of cell regulation |
| 09/04/2003 | US20030166665 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders |
| 09/04/2003 | US20030166664 E.g. 3-(1-(2-(5-(acetylamino)-2-methylphenyl)ethyl)piperidin--4-yl)-6-chloro-1H -indole; potent dopamine D4 ligands, dopamine antagonists; antiseratonin agents; psychoses; anxiolytic agents; antidepressants; side effects reduction |
| 09/04/2003 | US20030166663 E.g.,4-tert-butyl-N-(4-piperazin-1-yl-quinolin-6-yl)benzene-su lfonamide or 5-chloro-3-methyl-benzo(b)thiophene-2-sulfonic acid (4-piperazin-1-yl-quinolin-6-yl) amide; obesity; food intake reduction; bind to 5-HT6 receptors; antiseraton agents |
| 09/04/2003 | US20030166662 Administering a selective cyclic guanosine monophosphate (cGMP) phosphodiesterase 5 (PDE5) inhibitor, e.g. Rezulin, Avandia, Actos; hypotensive, antidiabetic and hypoglycemic agents; gout; anticoagulants; atherosclerosis; obesity |
| 09/04/2003 | US20030166661 Administering a synergistic mixture of L-arginine and a type V phosphodiesterase enzyme inhibitor as an antispasmodic agent to induce vasodilation; treating of cardiac pathologies as well as sexual disorders such as erectile dysfunction |
| 09/04/2003 | US20030166660 Administering a synergistic mixture of Imatinab and a telomerase inhibitor, e.g., telomestatin, for the delay of progression or treatment of leukemia or Imatinib-resistant leukemia; antiproliferative agents |
| 09/04/2003 | US20030166659 Administering a sustained release drug dosage-form including >5.0% by weight ranolazine in no more than two tablets per dose to maintain ranolazine plasma levels at a >850 ng base/mL for >24 hours; methacrylic acid copolymer binder |
| 09/04/2003 | US20030166657 Treating an optically pure enantimer of zopiclone with 1-chloroethyl chloroformate or an azodicarboxylate followed hydrolysis; modulation of benzodiazepine receptors; sleep and behavioral disorders; anxiolytic agents |
| 09/04/2003 | US20030166656 Derivatives of 4a-phenyl-pyrido(3,4-b)phenazine or 4a-phenyl-pyrid(3,4-b)acridine; side effect reduction; drug abuse; antidepressants; dysthymia; cognition activators; obsessive-compulsive and bipolar disorders; anxiolytic agents |
| 09/04/2003 | US20030166655 Acyclic nucleotide phosphodiesterase of type 4 inhibitors; antiinflammatory agents; antiallergens; antiarthritis agents, rheumatic diseases; AIDS; gastrointestinal, respiratory, brain, urogenital disorders |
| 09/04/2003 | US20030166654 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
| 09/04/2003 | US20030166653 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 09/04/2003 | US20030166652 Chemical compounds |
| 09/04/2003 | US20030166650 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents |
| 09/04/2003 | US20030166648 Felbamate derived compounds |
| 09/04/2003 | US20030166646 Nitric oxide synthase inhibitors such as 4-(morpholin-4-yl methyl)-4,5-dihydro-1,3-thiazol-2-ylamine, administered for prophylaxis of neurodegenerative diseases |
| 09/04/2003 | US20030166644 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 09/04/2003 | US20030166643 Substituted indenones as estrogenic agents |
| 09/04/2003 | US20030166642 Administering synergistic mixtures of phenothiazine and pentamidine derivatives as anticarcinogenic agents |
| 09/04/2003 | US20030166641 Heterocyclic amines such as 1-(3,4-methylenedioxyphenyl)-2-(5 -(3,4-dimethoxyphenyl)pyrimidin-2-yl)- 2,3,4,9-tetrahydro-1H-beta-carboline, used as enzyme inhibitors for prophylaxix of sexual disorders |
| 09/04/2003 | US20030166639 Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| 09/04/2003 | US20030166638 Technical field |
| 09/04/2003 | US20030166637 Amines such as 9-(4-(4-(benzothiazol-2-yl)-piperazin-1-yl)-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoroethyl) amide, used as microsomal triglyceride transfer protein antagonists, to prevent atherosclerosis or hyperlipemia |
| 09/04/2003 | US20030166634 Amines such as 3,3,5,5-Tetramethyl-1-vinylcyclohexanamine hydrochloride, used as N-methyl-D-aspartate (NMDA), serotonin and nicotinic acetylcholine receptor antagonists |
| 09/04/2003 | US20030166633 Pyridinylimidazoles |
| 09/04/2003 | US20030166632 Method for treating a disease or condition responsive to opening of C1C-2 channel |
| 09/04/2003 | US20030166631 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists |
| 09/04/2003 | US20030166630 Amino acid derivatives and their use as medicines |
| 09/04/2003 | US20030166629 Cyclic quaternary ammonium compounds |
| 09/04/2003 | US20030166628 Drugs such as 3-(4-chlorobenzo(b)thiophen-2-yl)-5,6-dihydro-imidazo(2,1-b)thiazole, used as hydroxytryptamine and/or noradrenaline reuptake inhibitors; anxiolytic agents |
| 09/04/2003 | US20030166627 6-Hydroxyequilenins as estrogenic agents |
| 09/04/2003 | US20030166626 7-Hydroxyepiandrosterone having neuroprotective activity |
| 09/04/2003 | US20030166625 Penetration enhancing and irritation reducing systems |
| 09/04/2003 | US20030166624 Sustained release mixtures of fluoxetine acetate or maleate, hydrocortisone, permeation intensifiers and cariers, applied to skin as topical antidepressants or for prophylaxis of obsessive compulsive disorder; drug delivery |
| 09/04/2003 | US20030166622 Vitamin D derivatives with acyloxy groups in the side chains, process for their production, and the use for the production of pharmaceutical agents |
| 09/04/2003 | US20030166621 Synergistic mixture comprising benzoic acid derivatives for use as anticarcinogenic agents, antitumor agents |
| 09/04/2003 | US20030166620 Antibacterial antibiotics; chemical intermediates |
| 09/04/2003 | US20030166619 N2O2- functionality is bound direct to a carbon atom; treating biological disorders hypertension, restenosis, impotency, genetic disorders or infections |
| 09/04/2003 | US20030166617 Combination therapies with vascular damaging activity |
| 09/04/2003 | US20030166615 A phenylamide indole compound derivatives for treating cancer, psoriasis, arteriosclerosis, immune system activity, Type II diabetes, and obesity |
| 09/04/2003 | US20030166614 Daily administering a mixture of anticholesterol agents comprising fish oil concentrate, niacin, and lecithin |
| 09/04/2003 | US20030166613 A macrocyclic diterpene plant extract for treating viral infections; A computer program product for storing the library information of candidate compounds |
| 09/04/2003 | US20030166610 Nutritional composition |
| 09/04/2003 | US20030166609 Medicine containing polysacccharide substances for activating apoptosis |
| 09/04/2003 | US20030166607 A trehalose solution comprising one or more metal ions, and neutral PH |
| 09/04/2003 | US20030166605 Method of minimizing damage to heart tissue during cardiac surgery and cardiac transplantation |
| 09/04/2003 | US20030166603 Using a p53- expressing viral vector as anticarcinogenic agents |
| 09/04/2003 | US20030166601 Drug delivery of the nucleic acid into a target tissue or cell, comprising a core complex contains a nucleic acid and complex forming agents, fusion with cell membranes with nuclear uptake; polymeric outer shell |
| 09/04/2003 | US20030166599 Uses of tgap7 for the modulation of leucocyte activation |
| 09/04/2003 | US20030166598 Such as 1,4-benzodiazipines; gene therapy; anticancer agents |
| 09/04/2003 | US20030166592 For treatment of metabolic disorders (diabetes, obesity) |
| 09/04/2003 | US20030166591 Testosterone-repressed prostate message-2 (TRPM-2); gene expression inhibition; increased antitumor activity |
| 09/04/2003 | US20030166590 Microsomal triglyceride transfer protein |
| 09/04/2003 | US20030166588 Splice-region antisense composition and method |
| 09/04/2003 | US20030166587 Compounds and methods for modulating activation of NF-kB |
| 09/04/2003 | US20030166585 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/04/2003 | US20030166584 For treatment of intestinal/hepatic cancer; improved drug delivery |
| 09/04/2003 | US20030166583 Such as epicatechin coadministered with retinoic acid; bioavailability |
| 09/04/2003 | US20030166582 Aryl fused azapolycyclic compounds |
| 09/04/2003 | US20030166581 Coadministered with caffeine, for prevention of seizures; for treatment of Parkinson's/Alzheimer's disease; dietetics; smoking cessation |
| 09/04/2003 | US20030166580 Substituted amino carboxamides for the treatment of alzheimer's disease |
| 09/04/2003 | US20030166579 Thrombin inhibitors comprising an aminoisoquinoline group |
| 09/04/2003 | US20030166578 Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| 09/04/2003 | US20030166576 Urokinase inhibitors |
| 09/04/2003 | US20030166562 Treatment for asthma or allergies |
| 09/04/2003 | US20030166554 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| 09/04/2003 | US20030166538 Isolated inflammation-related gene, the protein molecule encoded by the gene, and the use of the gene in diagnosis and treatment of inflammatory conditions. |
| 09/04/2003 | US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide |
| 09/04/2003 | US20030166535 Preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents. |
| 09/04/2003 | US20030166534 Suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, |
| 09/04/2003 | US20030166517 Galenical formulations |
| 09/04/2003 | US20030166516 Methods of treating, preventing, or inhibiting inflammation with exumolide compounds |
| 09/04/2003 | US20030166509 Pharmaceutical compositions comprising nanoparticles containing a sustained release bioactive agent, method of making such compositions, and method of therapy using such compositions. |
| 09/04/2003 | US20030166507 Water soluble paclitaxel derivatives |
| 09/04/2003 | US20030166503 Method for recognizing and determining GnRH receptors and use of GnRH agonist for decreasing the replication of malignant cells bearing GnRH receptors of tumors orginating in the nervous system and/or meninges and/or of Kaposi sarcoma |
| 09/04/2003 | US20030166289 Compositions and methods for regulating bacterial pathogenesis |
| 09/04/2003 | US20030166285 Methods and compositions for genetically modifying primate bone marrow cells |
| 09/04/2003 | US20030166284 Encoding hepatitis B virus surface antigen, treating hepatic diseases; inverted terminal repeats has the native D-sequences modified, some nucleotides are deleted or replaced; genetic engineering |
| 09/04/2003 | US20030166247 Transforming growth factor binding proteins; fusion proteins; knockout animal models; for treatment of osteoporosis/ fractures |
| 09/04/2003 | US20030166219 Mitogen-activated protein/extracellular signal-regulated kinases (MAP/ERK) |
| 09/04/2003 | US20030166175 Process for clavulanic acid production |
| 09/04/2003 | US20030166165 Comprises nucleotide sequences coding polyene macrolide antibiotics for use in veterinary medicine |
| 09/04/2003 | US20030166164 IL-17 like molecules and uses thereof |
| 09/04/2003 | US20030166153 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 09/04/2003 | US20030166150 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 09/04/2003 | US20030166045 Nucleotide sequences coding voltage gated calcium channels (VGCC) for treating neurological and cardiovascular disorders; anticonvulsant |
| 09/04/2003 | US20030166029 Obtaining an inhibitor of antibody-mediated lipid oxidation; drug screening; hemolysis; anticholesterol agents; cardiovascular disorder therapy |
| 09/04/2003 | US20030166024 Nucleotide sequences coding monoclonal antibody for the prevention, treatment and diagnosis of viral, inflammatory and tumor diseases; gene therapy |
| 09/04/2003 | US20030166023 Using genetic sensitivity markers to determine if taxol can be used to reduce the propagation of tumors |
| 09/04/2003 | US20030165950 Inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in |
| 09/04/2003 | US20030165928 Susceptibility to bone damage |
| 09/04/2003 | US20030165907 Human glycine transporter type 2 |
| 09/04/2003 | US20030165892 Unigene unidirectional antisense library |
| 09/04/2003 | US20030165878 Novel compositions and methods in cancer associated with altered expression of MCM3AP |
| 09/04/2003 | US20030165820 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 09/04/2003 | US20030165809 MARKs as modifiers of the p53 pathway and methods of use |